THERAPY DOSSIER · th-aa0dea5fc841

Dendrobium officinale polysaccharides (DOPS)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29074081 ↗2017Reported benefit

Protective roles and mechanisms of Dendrobium officinal polysaccharides on secondary liver injury in acute colitis.

MouseChemical/toxinBALB/cMale

Model: Secondary liver injury in acute colitis induced by 4% dextran sodium sulfate (DSS); LPS-stimulated RAW264.7 cells in vitro

DOPS attenuated DSS-induced hepatic damage, inflammation and oxidative stress in vivo and in vitro through TNF-alpha suppression and Nrf2 activation

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…